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Case Report
De Novo Interstitial Deletion of 9q
in a Pediatric Patient With Global
Developmental Delay
Dennis Keselman, BA1 , Ram Singh, PhD2,3, Ninette Cohen, PhD4,
and Zipora Fefer, MD5
Abstract
Cytogenomic microarray (CMA) methodologies, including array comparative genomic hybridization (aCGH) and single-
nucleotide polymorphism-detecting arrays (SNP-array), are recommended as the first-tier test for the evaluation of imbal-
ances associated with intellectual disability, autism, and multiple congenital anomalies. The authors report on a child with global
developmental delay (GDD) and a de novo interstitial 7.0 Mb deletion of 9q21.33q22.31 detected by aCGH. The patient that the
authors report here is noteworthy in that she presented with GDD and her interstitial deletion is not inclusive of the 9q22.32
locus that includes the PTCH1 gene, which is implicated in Gorlin syndrome, or basal cell nevus syndrome (BCNS), has not been
previously reported among patients with a similar or smaller size of the deletion in this locus suggesting that the genomic contents
in the identified deletion on 9q21.33q22.31 is critical for the phenotype.
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Global developmental delay (GDD) is a subset of developmen-
tal disabilities defined as significant delay in 2 or more devel-
opmental components, including gross/fine motor, speech/
language, cognition, social/personal, and activities of daily liv-
ing.1 Significant delay is specifically defined as performance 2
standard deviations or greater below the mean on standardized
testing compared to peers of the same age. Global develop-
mental delay affects approximately 1%–3% of children, high-
lighting the necessity to determine specific causes for it.
Current American Academy of Neurology (AAN) and Child
Neurology Society (CNS) guidelines2 for the evaluation of
children with GDD begin with obtaining a detailed history,
an electroencephalogram (EEG) test, metabolic studies, and
T4 levels if the universal newborn screening was not done,
screening for autism or language disorders, and referring to
audiology and ophthalmology screening. Further studies
include brain magnetic resonance imaging (MRI), lead screen,
cytogenetic screen, fragile X screen, metabolic testing, subte-
lomeric rearrangement testing, Rett syndrome testing, and
genetics consultation. Importantly, clinical experience and
analytical reasoning guide the decisions to pursue appropriate
and relevant testing.
While GDD is one of the most common reasons for referral
to a pediatric neurologist, many cases of GDD do not have
definitive etiologic diagnoses because of a lack of imaging
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abnormalities, a normal metabolic screen, and an unremarkable
medical and family history.3 The advent of cytogenetic and
molecular studies has drastically improved our ability to
determine specific diagnoses in cases of GDD, leaving only a
minority of children with undetermined etiologies of GDD.4
Accurate etiologic determination of GDD has specific impli-
cations regarding treatment, prognosis, management of any
associated conditions, and prevention.1 As with many other
chronic illnesses, determining the specific cause helps
empower the family to advocate for the child, plan for the
child’s future, and limit further unnecessary testing.
Patient Description
This female child was initially referred to our pediatric neurol-
ogy clinic at 12 months of age for evaluation of GDD.
Birth and Neonatal History
The patient had an unremarkable vaginal delivery at term to a
gravida 2, para 1, 36-year-old mother with a birth weight of
3402 g. There were no complications with pregnancy or deliv-
ery. She was found to have a small atrial septal defect (ASD)
and physiologic pulmonary stenosis (PPS) at 2 months of age,
deemed insignificant for that age. By 8 months of age, the ASD
had spontaneously closed. At that time, she was noted to have
an unremarkable physical examination and has been thriving at
home, feeding without difficulty, gaining weight, and develop-
ing appropriately.
Developmental Delay
Her motor development was delayed. Her mother first became
concerned about her development at 5 months of age because
she was not supporting her weight when sitting, and this
continued until 12 months of age. At 11 months of age, she
was diagnosed with hypotonia and qualified for physical
therapy and occupational therapy. She began rolling over at
14 months and crawling at 17 months. At 19 months, she was
able to pull herself up to stand and required holding on to
maintain her stance.
Her language development was also delayed. At 12 months,
she followed simple directions such as “no,” clap her hands,
and touch her nose. She was able to call her dad specifically but
did not speak other words. She did not wave goodbye. At 14
months, she was able to say “hi,” “bye,” and “dada.” At 19
months, she had a vocabulary of about 10 words.
The family history was unremarkable. Her elder sister, who
was 4 years old, had no developmental issues.
Neurologic Evaluation
During her initial neurology evaluation at 12 months of age,
head circumference was 47 cm, 91st percentile, weight in the
89th percentile, and a height in the 64th percentile. Her father,
mother, and 4-year-old elder sister’s head circumferences are
in the 98th, 90th, and 75th percentiles, respectively. Thus, her
head circumference can be proportional to her other growth
parameters and might be familial. Her physical examination
at that time revealed intermittent bilateral exotropia, which had
been witnessed since the age of 7 months. She pulled to sit well,
did not roll over, did not crawl, and did not extend her lower
extremities in an attempt to stand. Otherwise, she had a non-
focal examination. The parents denied developmental regres-
sion and denied any seizure episodes, although noted that the
child had 3 episodes of “eye rolling” during bowel movements.
Further Workup
An EEG test at that time was normal. A brain MRI at 13 months
showed an incidental calvarian dermoid cyst within the left
subcutaneous tissues of the level of C1 to C2 but was otherwise
unremarkable. Metabolic workup was negative.
An ophthalmology evaluation determined that her exotropia
would be corrected with glasses and that she has bilateral
refractive amblyopia secondary to astigmatism. An otolaryn-
gology evaluation revealed that the patient has ankyloglossia, a
congenital anomaly characterized by a short frenulum.
Genetic Testing
The patient was evaluated by a medical geneticist at 14 months
of age, and CMA testing was ordered to rule out unbalanced
structural and numerical chromosomal abnormalities. Cytoge-
nomic microarray testing using the SurePrint G3 ISCA
CGHþSNP 4x180 k microarray (Agilent Technologies, Santa
Clara, CA)5,6 led to the identification of a heterozygous 7.0-Mb
deletion of chromosome 9q21.33q22.31 (chr9:87,331,806-
94,336,693) (Figure 1). The deletion included 45 genes and
transcripts and had only minimal overlap with copy number
variants (CNVs) reported among healthy individuals in the
Database of Genomic Variants (DGV; http://dgv.tcag.ca)
(Figure 2).7 The interstitial 9q21.33q22.31 deletion was con-
firmed by fluorescence in situ hybridization (FISH) in all inter-
phase nuclei using a bacterial artificial chromosome (BAC)
probe that hybridized to the 9q21.33 region and a control probe
specific to the subtelomeric region of chromosome 9q (Figure
3). Subsequent parental CMA testing determined that the 7.0-
Mb interstitial deletion was not inherited and, therefore,
occurred de novo in this patient (Figure 4). The family declined
further testing with whole exome sequencing (WES) or tar-
geted gene panels.
Continued Care
The patient continued to have a nonfocal neurologic examina-
tion at 19 months. At 25 months of age, the patient underwent
an elective excision of the calvarian lesion, with an uneventful
surgery and recovery.
Discussion
Interstitial deletions of chromosome 9q are rare and are char-
acterized with multiple congenital anomalies, dysmorphic
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features, developmental delay, and intellectual disability. The
specific deletion detected in our patient includes over 45 genes
and transcripts, among them 3 previously reported Mendelian
disease genes (NTRK2, SECISBP2, and AUH). Mutations in
NTRK2 are associated with a condition involving mood disor-
ders, Alzheimer disease, autism, and developmental delays.
Figure 1. (A) Location of the deletion within banding region 9q21.33q22.31 and (B) close view shows a 7.0-Mb deletion overlaid on the raw log2
probe plot. Chromosomal microarray analysis was performed using array comparative genomic hybridization (aCGH) with Agilent’s SurePrint
G3 4x180 k CGHþ single-nucleotide polymorphism (SNP). Array CGH data were analyzed using Cytogenomics (v.3.0.2.11, Agilent) and Bench
LAB CNV (v5.1.1, Cartagenia).
Figure 2. The size, extent, and genomic content of the deletion in this patient. Genomic coordinates from array comparative genomic
hybridization (aCGH, chr9:87,331,806-94,336,693 [hg19]) were analyzed on UCSC genome browser. UCSC genome browser tracks (hg19)
showing (A) all genes (RefSeq) (B) OMIM genes (green bars) (C) Database of Genomic Variants (DGV).
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Mutations in the SECIBP2 and AUH genes are associated
with autosomal recessive conditions: an abnormal thyroid
metabolism disorder and type 1 methylglutaconic aciduria,
respectively.8–10
The NTRK2 (neurotrophic receptor tyrosine kinase 2) gene
localizes to chromosome 9q21.33 and contains 23 exons.
NTRK2 encodes TrkB, a membrane receptor kinase that auto-
phosphorylates through the MAPK signaling pathway when
activated by neurotrophin binding.11 Gene variants involving
the NTRK2 gene are associated with a number of neurological
and psychiatric disorders such as mood disorders,12 vulnerabil-
ity to nicotine or alcohol dependence,13,14 Alzheimer dis-
ease,15,16 and autism.17
The SECISBP2 (selenocysteine insertion sequence-binding
protein 2) gene, also known as SBP2, localizes to chromosome
9q22.2. The mutation of this gene leads to defects in incorpora-
tion of selenocysteine and, as a result, leads to reduced synth-
esis of most of the 25 known human selenoproteins.18
Deficiencies in selenoproteins have been implicated in azoos-
permia, axial muscular dystrophy, photosensitivity, immuno-
deficiencies, and abnormal thyroid function.18,19
The AUH (AU RNA binding methylglutaconyl-CoA hydra-
tase) gene localizes to chromosome 9q22.31. Mutations in this
gene are implicated in 3-methylglutaconic aciduria type I, an
autosomal recessive disorder of leucine degradation.20 Speech
delay and GDD are often prominent symptoms of the resulting
disease.20,21
To elucidate the clinical significance of the identified
deletion, the authors reviewed published case reports in the
literature and evaluated the phenotypes. Table 1 presents the
published loci overlapping with that of the current study.
Twenty-eight cases of interstitial 9q deletions were found span,
flanked, or partially overlapped with the current case’s
deletion.8–10,22–34 The clinical features of individuals with
deletion of 9q varied with few common features.
Gorlin syndrome, also known as the nevoid basal cell car-
cinoma syndrome (NBCCS) or basal cell nevus syndrome
(BCNS), is a disorder involving the PTCH1 gene found on
9q22.32.28 PTCH1 was not implicated in this study because
the deletion found was 9q21.33q22.31, and therefore did not
involve 9q22.32. However, much of the literature involving 9q
interstitial deletions involves the Gorlin syndrome. It has been
proposed that the diagnosis of Gorlin syndrome can be made by
Figure 3. The identified deletion was confirmed by fluorescence in
situ hybridization (FISH) using a bacterial artificial chromosome (BAC)
probe targeted to the 9q21.33 region (RP11- 91M3, Empire Geno-
mics) and a control probe specific to the subtelomeric region of
chromosome 9q (TelVysion 9q, D9S325, Abbott Molecular). Loss of
the green fluorescent hybridization signal confirmed the deletion in
the nuclei. Chromosomes were stained with DAPI.
Figure 4. Parental analysis by array comparative genomic hybridization (aCGH) showed that neither parent was a carrier of this aberration,
indicating that the deletion occurred de novo in the proband.
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meeting 2 major criteria and 1 minor criteria or 1 major criteria
and 3 minor criteria.35 The major criteria include lamellar cal-
cification of the falx, jaw keratocysts, palmar/plantar pits, mul-
tiple basal cell carcinomas (>5 in a lifetime or one before the
age of 30 years), and first-degree relatives with Gorlin syn-
drome.35 The minor criteria include child medulloblastomas,
lympho-mesenteric or pleural cysts, macrocephaly, cleft lip/
palate, vertebral/rib anomalies, preaxial or postaxial polydac-
tyly, ovarian/cardiac fibromas, and ocular anomalies.35 Other
features that are not typically associated with Gorlin syndrome,
such as metopic craniosynostosis, hydrocephalus, macrosomia,
and developmental delay, were seen in high frequencies in
cases with confirmed pathogenic variants of PTCH1.33 The
patient involved in this study did not meet any of the major
or minor criteria as anticipated by the lack of involvement of
9q22.32 and PTCH1.
Our patient has a complex phenotype consisting of GDD,
exotropia, ankyloglossia, and a calvarian dermoid cyst. Here-
tofore, her clinical presentation is less severe than those docu-
mented in cases with CNVs of the aforementioned genes that
are affected by her interstitial deletion. Therefore, it appears
that this patient’s clinical synopsis is not predicted simply by
the roles of each of the genes involved in this novel interstitial
deletion.
Table 1. Published case reports in the literature of loci overlapping with that of the current study.
Source Current study Zhang et al. 2015
Reichert et al.
2015 Pua et al. 2014 Garavelli et al. 2013
Isidor et al. 2013
Patient 1 Patient 2
Inheritance De novo ? De novo De novo De novo De novo De novo
Position (Mb) 9q21.33q22.31 Discontinuous 9q21.33-9q22.33 9q22.31q22.32 9q21.32q21.33 9q22.2q31.1 9q22.3 9q22.3
Deletion size (Mb) 7.0 Variable 3.99 2.6 10.9 1.7-8.9 1.7-8.9
OMIM disease genes NTRK2, SECISBP2,
AUH
PTCH1, NTRK2, SECISBP2,
AUH, FBP1, HSD17B3
PTCH1, FANCC NKGD2, KIF27, UBQLN1,
HNRNPK, RMI1, NTRK2
PTCH1, FANCC PTCH1 PTCH1
Gorlin syndrome – – – – þ þ þ
Cardiac tumors – þ – – – – –
Developmental delay þ – – – þ þ þ
Hydrocephalus – – – – þ – –
Metopic fusion – – þ – – – –
Macrosomia – – þ – – – –
Macrocephaly – – – – – – –
Hearing Loss – – – – – – –
Atrial septal defect þ – – þ – – –
Epilepsy – – – – – – –
Strabismus þ – – – – – –
Pulmonary stenosis þ – – – – – –
Failure to thrive – – – – – – –
Recurrent infection – – – þ – – –
Other Calvarian cyst,
ankyloglossia,
hypotonia
Ventriculomegaly Craniofacial abnormalities,
bicornuate uterus, bilateral
hip dislocation, hypotonia
Wilms tumor, multiple
tumors
Long and thin
fingers,
dolichocephaly
Wilms tumor,
macroglossia
Source
Siggberg et al.
2011 Mosterd et al. 2009
Yamamoto et al. 2009
Nowakowska
et al. 2007 Cajaiba et al. 2006Patient 1 Patient 2
Inheritance De novo De novo De novo De novo ? ?
Position (Mb) 9q22.2q22.32 9q22 9q21.33q22.33 9q21.33q31.1 9q22.1q22.32 9q22q32
Deletion size (Mb) 5.3 11.24 15.33-16.04 18.08-18.54 7.7 ?
OMIM disease genes ROR2, SYK PTCH1, FANCC, XPA PTCH1 PTCH1 PTCH1, ROR2 PTCH1
Gorlin syndrome – þ þ þ þ þ
Cardiac tumors – – – – – –
Developmental delay – – þ – – –
Hydrocephalus – – – – – –
Metopic fusion – – – þ – –
Macrosomia – – þ þ – –
Macrocephaly – – – þ – –
Hearing Loss – – – – – –
Atrial septal defect – – – – – –
Epilepsy – – þ þ – –
Strabismus – – þ – – –
Pulmonary stenosis – – – – þ –
Failure to thrive – – þ – – –
Recurrent infection þ – – – – –
Other Craniofacial
abnormalities,
dysarthria
Overfriendliness,
attention deficit,
ventriculomegaly,
ganglioglioma
Craniofacial abnormalities, overfriendliness, attention deficit and
hyperactivity, retinal detachment, cataract, glaucoma, functional
thyroid tumor, craniosynostosis, double urethra
Hypoplastic
clavicles,
craniofacial
abnormalities
Rhabdomyosarcoma,
Wilms tumor,
macroglossia
(continued)
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In conclusion, the authors present a unique case of a 7.0-Mb
9q interstitial deletion at 9q21.33q22.31 in a patient who pre-
sented with GDD. Of note, there are very few cases of over-
lapping deletions that do not fit criteria for Gorlin syndrome.
As there are not many reports of deletions spanning the seg-
ment 9q21.33q22.31 in the literature, follow-up would be
invaluable in order to extend existing knowledge of this disease
course and progression. Future reports of gene deletions in the
9q21.33q22.31 segment would also be beneficial in helping
elucidate the disease progression and the biological mechan-
isms that are present.
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Table 1. (continued)
Source
Chen et al.
2006 Chen et al. 2005 Boonen et al. 2005 L’Hermine et al. 2002
Shimkets et al. 1996
Patient 1 Patient 2
Inheritance De novo De novo De novo De novo De novo De novo
Position (Mb) 9q22.3q31.3 9q21.1q22.2 9q21.3q31 9q22.2q31.1 9q22 9q22q32
Deletion size (Mb) 12 ? 15 ? 10-16 cM 22-39 cM
OMIM disease genes PTCH1 ? PTCH1, ROR2 ? PTCH1 PTCH1
Gorlin syndrome þ – þ – þ þ
Cardiac tumors – – – – – –
Developmental delay – – þ – – –
Hydrocephalus – – – – þ –
Metopic fusion – – – – – –
Macrosomia þ – – – – –
Macrocephaly þ – – – þ –
Hearing Loss – – – – þ þ
Atrial septal defect – – – – – –
Epilepsy – – – – – –
Strabismus – – þ – – –
Pulmonary stenosis – – þ – – –
Failure to thrive – – þ – – þ
Recurrent infection – – þ – – –
Other Craniofacial
abnormalities,
thick nuchal
fold
Epicanthic folds, abnormal palmar crease, bilateral testes retention,
bilateral postaxial polydactilia pedes, excess nuchal skin, craniofacial
abnormalities, ventriculomegaly, bilateral inguinal hernias
IUGR, female
pseudohermaphroditism,
craniofacial abnormalities
Bilateral inguinal hernias,
growth delay, corpus
collosum agenesis
Congenital
anomalies
of the
great
vessels
Source
Muller et al. 2012
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Inheritance De novo De novo De novo De novo De novo De novo De novo De novo De novo De novo
Position (Mb) 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3 9q22.3
Deletion size (Mb) 20.5 10.85 9.85 8.28 8.07 4.5 2.03 1.84 1.08 0.352
OMIM disease genes PTCH1 PTCH1 PTCH1 PTCH1 PTCH1 PTCH1 PTCH1 PTCH1 PTCH1 PTCH1
Gorlin syndrome þ þ þ þ þ þ þ þ þ þ
Cardiac tumors – – – – – – – – –
Developmental delay – þ þ þ þ þ þ þ þ þ
Hydrocephalus – þ þ þ þ – – – þ –
Metopic fusion þ – – – þ – þ þ – –
Macrosomia – – – – – – + þ – –
Macrocephaly – – – – – – – – – –
Hearing Loss – – – – – – – – – –
Atrial septal defect – – – – – – – – – –
Epilepsy – – – – – – – – – –
Strabismus – – – – – – – – – –
Pulmonary stenosis – – – – – – – – – –
Failure to thrive – – – – – – – – – –
Recurrent infection – – – – – – – – – –
Other
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